Pfizer Ltd, the Indian arm of the global pharmaceutical giant, announced its Q4 financial results for the fiscal year ending March 31, 2026, revealing a significant 39.1% slump in net profit. The company's net profit fell to Rs 200 crore in the fourth quarter, compared to Rs 311 crore in the corresponding period last year.
Despite the notable profit decline, the company's board delivered positive news for shareholders, recommending a final dividend of Rs 75 per equity share. This represents a substantial 750% payout on shares with a face value of Rs 10 each. The record date for determining shareholders' eligibility for this dividend has been fixed for Friday, July 17, 2026.
Financial Performance Overview
While net profit saw a downturn, other financial metrics presented a mixed picture. Pfizer Ltd's revenue for Q4 climbed by 6.3%, reaching Rs 629.2 crore, up from Rs 592 crore recorded in the same quarter of the previous fiscal year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw a modest increase of 3.7%, rising to Rs 236 crore from Rs 228 crore year-over-year.
However, the operating margin experienced a slight contraction, settling at 37.5% compared to 38.4% in the corresponding quarter last year. Following the earnings announcement, Pfizer Ltd's stock reacted by falling 1.77% to Rs 4645 in the current trading session, bringing the firm's market capitalization to Rs 21,300 crore.
About Pfizer Ltd India
Pfizer Ltd operates across various therapeutic areas in India, including anti-infectives, cardiology, pain management, and immunology. The company is involved in both the manufacturing and marketing of a wide range of medicines and vaccines, contributing significantly to the country's pharmaceutical landscape.